Red blood cell alloantibodies (RBC alloantibodies)

Recipient alloantibodies binding to donor red blood cell (RBC) surface antigens is the primary pathological event in alloimmune hemolytic conditions, such as hemolytic transfusion reactions (HTR) and hemolytic disease of the fetus and newborn (HDFN) (StatPearls, NBK557423). These antibodies, usually of the IgG class, are formed when a recipient's immune system recognizes foreign antigens on transfused RBCs or fetal RBCs during pregnancy (PubMed, 32810227). Upon binding to the RBC surface, these antibodies facilitate cell destruction through opsonization, leading to splenic macrophage-mediated phagocytosis, or through the activation of the classical complement pathway (NCBI, PMC6153391). In clinical practice, this interaction is detected using the Indirect Antiglobulin Test (IAT) to screen for circulating antibodies and the Direct Antiglobulin Test (DAT) to identify antibodies already bound to cells (StatPearls, NBK482202). Therapeutic interventions aim to mitigate the effects of these antibodies by inhibiting their production (e.g., Rituximab, Daratumumab), accelerating their clearance via neonatal Fc receptor (FcRn) blockade (e.g., Nipocalimab), or preventing downstream complement-mediated damage (e.g., Eculizumab) (NEJM, NEJMoa2312678). Managing this target is crucial for ensuring transfusion safety and preventing severe fetal anemia or hydrops fetalis in sensitized pregnancies. The specificity of these antibodies varies across blood group systems, including Rh, Kell, Duffy, and Kidd, each presenting unique clinical risks (PubMed, 30263210). Recent drug development has focused on FcRn inhibitors, which provide a targeted approach to reducing pathogenic IgG levels without broad immunosuppression (NCBI, PMC8283715).

Other names

Erythrocyte alloantibodiesBlood group antibodiesAnti-erythrocyte antibodiesAlloimmune antibodiesRed cell antibodies

Neonatal Fc receptor (FcRn) antagonism, B-lymphocyte antigen CD20 inhibition, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibition, Complement C5 inhibition, and Complement C3 inhibition.